Sporadic Creutzfeldt Jakob disease: Case series in Peru
Main Article Content
Description of the cases: A series of 6 cases with a probable diagnosis of sporadic CJD, treated in a Peruvian national reference hospital, are presented.
Clinical findings: The relevant clinical signs were rapidly progressive dementia and myoclonus, followed by akinetic mutism and pyramidal signs.
Treatment and results: Of the cases presented, 80% were men, with an average age of presentation of 65 years and a duration from diagnosis to death of 6.5 months. Laboratory tests, images (Brain Resonance), and protein dosage 14.3.3 were performed to support the clinical suspicion. There is no effective treatment for said pathology at the moment.
Clinical Relevance: Creutzfeldt-Jakob disease (CJD) is a progressive, fatal, neurodegenerative disease of low prevalence and incidence. Great clinical suspicion and the exclusion of other etiologies are required. Currently, there is no treatment for this entity, and there is a high probability of death before one year.
- Prion Diseases
- Prions
- Creutzfeldt-Jakob Syndrome
- Dementia
- Peru
Baldwin KJ, Correll CM. Prion Disease. Seminars in Neurology [Internet]. 2019 Aug 1;39(4):428-39. Available from: https://pubmed.ncbi.nlm.nih.gov/31533183/ https://doi.org/10.1055/s-0039-1687841
Fragoso DC, Gonçalves Filho AL da M, Pacheco FT, et al. Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis. RadioGraphics. 2017 Jan;37(1):234-57. https://doi.org/10.1148/rg.2017160075
Tee BL, Longoria Ibarrola EM, Geschwind MD. Prion Diseases. Neurol Clin. 2018;36(4):865-897. https://doi.org/10.1016/j.ncl.2018.07.005
Wang H, Rhoads D, Appleby B. Human prion diseases. Current opinion in infectious diseases 2019 Jun;32(3):272-276. https://doi.org/10.1097/QCO.0000000000000552
Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. The Lancet Infectious Diseases [Internet]. 2020 Jan 1;20(1):e2-10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31876504 https://doi.org/10.1016/S1473-3099(19)30615-2
Centers for Disease Control and Prevention. Occurrence and Transmission [Internet]. CDC. 2019. Available from: https://www.cdc.gov/prions/cjd/occurrence-transmission.html
Zerr I, Hermann P. Diagnostic challenges in rapidly progressive dementia. Expert Review of Neurotherapeutics. 2018 Sep 17;18(10):761-72. https://doi.org/10.1080/14737175.2018.1519397
Figgie MP, Appleby BS. Clinical Use of Improved Diagnostic Testing for Detection of Prion Disease. Viruses. 2021 Apr 28;13(5):789. https://doi.org/10.3390/v13050789
Inga Zerr, M.D. Laboratory Diagnosis of Creutzfeldt-Jakob Disease. N Engl J Med 2022;386:1345-50. DOI: 10.1056/NEJMra2119323 https://doi.org/10.1056/NEJMra2119323
Hermann et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021 March ; 20(3): 235-246. doi:10.1016/S1474-4422(20)30477-4. https://doi.org/10.1016/S1474-4422(20)30477-4
Zerr I, Kallenberg K, Summers DM et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132: 2659-68. https://doi.org/10.1093/brain/awp191
Renzo Manara et. al. MRI abnormalities in Creutzfeldt-Jakob disease and other rapidly progressive dementia. Journal of Neurology (2024) 271:300-309 https://doi.org/10.1007/s00415-023-11962-1 https://doi.org/10.1007/s00415-023-11962-1
Andrew G.B. Thompson, Simon H. Mead , Review: Fluid biomarkers in the human prion diseases. Ymcne (2018), https://doi.org/10.1016/j.mcn.2018.12.003
Altuna, M.; Ruiz, I.; Zelaya, M.V.; Mendioroz, M. Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review. Medicina 2022, 58, 473. https:// doi.org/10.3390/medicina58040473 https://doi.org/10.3390/medicina58040473
Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012 ;79(14):1499-506. https://doi.org/10.1212/WNL.0b013e31826d5fc3
Miranda et. al. Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?. Academia Brasileira de Neurologia 2022. DOI https://doi.org/ 10.1055/s-0042-1755341 https://doi.org/10.1055/s-0042-1755341
Copeland R, Amin S, Donato A. The Management of Newly Diagnosed Probable Creutzfeldt-Jakob Disease In Acute Rehabilitation Setting: A Case Report. Advances in Clinical Medical Research and Healthcare Delivery. 2022; 2(3). doi: 10.53785/2769-2779.1116. https://doi.org/10.53785/2769-2779.1116
Downloads

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use